FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, specifically to a new insulin agonist conjugated with incretin protein, and can be used in medicine.
EFFECT: conjugate of insulin and incretin of the present invention has agonist activity both on the insulin receptor and on the corresponding incretin receptor, and can be used for the treatment of juvenile diabetes and adult diabetes at a later stage.
8 cl, 15 dwg, 5 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY | 2011 |
|
RU2604067C2 |
| AMIDE-BASED PRODRUGS OF GLUCAGON SUPERFAMILY PEPTIDES | 2009 |
|
RU2550696C2 |
| GLUCAGON ANALOGUES, POSSESSING HIGHER SOLUBILITY AND STABILITY IN BUFFERS WITH PHYSIOLOGICAL Ph VALUES | 2009 |
|
RU2560254C2 |
| PEPTIDE PRO-DRUGS OF AMIDE GLUCAGON SUPERFAMILY | 2011 |
|
RU2580317C2 |
| GLUCAGON ANALOGUES, HAVING HIGH SOLUBILITY IN PHYSIOLOGICAL pH BUFFERS | 2008 |
|
RU2477286C2 |
| NEW METHOD FOR OBTAINING LONG-ACTING DRUG CONJUGATE BY PRODUCING INTERMEDIATE | 2019 |
|
RU2805873C2 |
| COMPOSITION FOR TREATING HYPERLIPIDEMIA CONTAINING AN OXYNTOMODULIN DERIVATIVE | 2013 |
|
RU2768853C1 |
| CONJUGATE CONTAINING OXINTOMODULIN AND IMMUNOGLOBULIN FRAGMENT, AND ITS APPLICATION | 2012 |
|
RU2733544C2 |
| CONJUGATE OF LONG-ACTING PHYSIOLOGICALLY ACTIVE SUBSTANCE AND ITS USE | 2018 |
|
RU2773823C2 |
| FUSED DRUG CONSTRUCTS AND CONJUGATES | 2005 |
|
RU2428431C2 |
